NCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
Clinical Trials
15 trialsNCT03032107 2025-01-27
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03364348 2022-10-19
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Stanford University
Phase 1 Completed
NCT02562378 2022-02-23
THELMA
MedSIR
Phase 1 Completed
NCT01976169 2022-02-08
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01983501 2020-09-21
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Seagen Inc.
Phase 1 Completed
NCT02038010 2020-06-29
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Northwestern University
Phase 1 Completed
NCT02605915 2020-02-05
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02073916 2019-04-16
STELA
The Methodist Hospital Research Institute
Phase 1 Completed
NCT03153163 2018-11-23
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT01816035 2017-05-23
Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
University of Washington
Phase 1 Completed
NCT00928330 2016-11-02
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Genentech, Inc.
Phase 1 Completed
NCT01513083 2016-11-02
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Hoffmann-La Roche
Phase 1 Completed
NCT00932373 2015-08-26
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Genentech, Inc.
Phase 1 Completed
NCT00991562 2014-11-21
IMGN901 in Combination With Lenalidomide and Dexamethasone
ImmunoGen, Inc.
Phase 1 Completed